
Leyre Mestre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/942870/publications.pdf Version: 2024-02-01



I EVDE MESTDE

#	Article	IF	CITATIONS
1	Anandamide enhances ILâ€10 production in activated microglia by targeting CB ₂ receptors: Roles of ERK1/2, JNK, and NFâ€₽B. Glia, 2010, 58, 135-147.	2.5	149
2	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. Journal of Neurochemistry, 2005, 92, 1327-1339.	2.1	131
3	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease, 2005, 20, 207-217.	2.1	131
4	Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, 166, 40-55.		127
5	A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2012, 7, 1002-1016.	2.1	119
6	Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. British Journal of Pharmacology, 2005, 145, 441-448.	2.7	114
7	CD200 D200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia, 2012, 60, 1437-1450.	2.5	113
8	Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Molecular and Cellular Neurosciences, 2007, 34, 551-561.	1.0	103
9	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. European Journal of Neuroscience, 2008, 28, 633-641.	1.2	103
10	A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochemical Pharmacology, 2009, 77, 86-100.	2.0	85
11	Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus. Progress in Neurobiology, 2013, 101-102, 46-64.	2.8	78
12	Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System. Current Pharmaceutical Design, 2014, 20, 4707-4722.	0.9	69
13	The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain, Behavior, and Immunity, 2011, 25, 736-749.	2.0	63
14	The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochemical Pharmacology, 2006, 72, 869-880.	2.0	51
15	Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1receptors. Journal of Neuroinflammation, 2011, 8, 102.	3.1	51
16	2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination. Journal of Neuroscience, 2017, 37, 8385-8398.	1.7	47
17	Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. Journal of Neuroinflammation, 2018, 15, 64.	3.1	44
18	Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E2. Biochemical Journal, 2008, 409, 761-770.	1.7	40

Leyre Mestre

#	Article	IF	CITATIONS
19	2â€AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. Glia, 2018, 66, 1447-1463.	2.5	40
20	Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2008, 12, 185-195.	1.5	37
21	Chemical Probes for the Recognition of Cannabinoid Receptors in Native Systems. Angewandte Chemie - International Edition, 2012, 51, 6896-6899.	7.2	37
22	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 1374.	2.2	35
23	The Role of Cannabinoid System on Immune Modulation: Therapeutic Implications on CNS Inflammation. Mini-Reviews in Medicinal Chemistry, 2005, 5, 671-675.	1.1	33
24	A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells, 2020, 9, 906.	1.8	31
25	How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes, 2020, 12, 1813532.	4.3	24
26	Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. Frontiers in Cellular Neuroscience, 2020, 14, 34.	1.8	23
27	Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis. NeuroImmunoModulation, 2007, 14, 182-187.	0.9	20
28	Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis. Journal of Neuroinflammation, 2020, 17, 88.	3.1	20
29	Chapter 9 The Endocannabinoid Anandamide. Vitamins and Hormones, 2009, 81, 207-230.	0.7	19
30	Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. Neurobiology of Disease, 2020, 143, 104994.	2.1	18
31	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 920-937.	2.1	18
32	Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters, 2012, 508, 67-72.	1.0	13
33	2â€arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions. Glia, 2020, 68, 1255-1273.	2.5	13
34	Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	5
35	Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis. Aging Cell, 2021, 20, e13440.	3.0	4
36	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics, 2022, 14, 1420.	2.0	3